SCHEMBL10979352

SCHEMBL10979352

CCOC(=O)C(C)Oc1ccc(Br)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.60
L3MBTL1 Q9Y468 3/20 0.60
KMT2A Q03164 3/20 0.57
GAA P10253 2/20 0.56
MEN1 O00255 2/20 0.56
EPHX2 P34913 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
LDHA P00338 1/20 0.49
MAPT P10636 2/20 0.47
MAPK1 P28482 2/20 0.45
S1PR4 O95977 1/20 0.45
S1PR1 P21453 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TSHR P16473 1/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH2 P05091 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31053227 1.00 LMNA (0.60) LMNAL3MBTL1KMT2AGAAMEN1
SCHEMBL11158149 0.95 LMNA (0.56) LMNAL3MBTL1KMT2AGAAMEN1
SCHEMBL7976961 0.87 L3MBTL1 (0.51) LMNAL3MBTL1KMT2AGAAMEN1
SCHEMBL29039579 0.87 KMT2A (0.48) LMNAL3MBTL1KMT2AGAAMEN1
SCHEMBL5205374 0.86 LMNA (0.63) LMNAL3MBTL1KMT2AGAAMEN1
SCHEMBL11548487 0.86 L3MBTL1 (0.63) LMNAL3MBTL1KMT2AGAAMEN1
SCHEMBL18562096 0.86 LMNA (0.63) LMNAL3MBTL1KMT2AGAAMEN1
SCHEMBL9063261 0.86 LMNA (0.63) LMNAL3MBTL1KMT2AGAAMEN1
SCHEMBL9857703 0.86 LMNA (0.63) LMNAL3MBTL1KMT2AGAAMEN1
SCHEMBL11717559 0.85 KMT2A (0.49) LMNAL3MBTL1KMT2AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220142961-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-05-12 US disclosed
US-11318111-B2 CCL5 inhibitors LAPKO INC (US) 2022-05-03 US disclosed
US-20210196665-A1 CCL5 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-07-01 US disclosed
US-10940132-B2 CCL5 inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-03-09 US disclosed
US-20200138766-A1 CCL5 INHIBITORS LAPKO INC. DBA AFECTA PHARMACEUTICALS 2020-05-07 US disclosed
US-20140213538-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. 2014-07-31 US disclosed
WO-2014113485-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2014-07-24 WO disclosed
EP-0083228-B1 PHARMACEUTICALLY ACTIVE PHENYLCARBOXYLIC ACID DERIVATIVES ICI AMERICAS INC. (US) 1985-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213538-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 LMNA 701/4885L3MBTL1 2087/4885KMT2A 2450/4885
US-20220142961-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 LMNA 4533/4885L3MBTL1 1170/4885KMT2A 4842/4885
US-20200138766-A1 CCL5 INHIBITORS CCL5, CCL11, CCR5 LMNA 4533/4885L3MBTL1 1170/4885KMT2A 4842/4885
US-20210196665-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 LMNA 4533/4885L3MBTL1 1170/4885KMT2A 4842/4885
US-10940132-B2 CCL5 inhibitors CCL5, CCL11, CCR5 LMNA 4533/4885L3MBTL1 1170/4885KMT2A 4842/4885
US-11318111-B2 CCL5 inhibitors CCL5, CCL11, CCR5 LMNA 4533/4885L3MBTL1 1170/4885KMT2A 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.